Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, shared an article by Saad Z. Usmani, et al. on X:
“CEPHEUS out!
Congratulations Saad Z. Usmani, et al.
PFS with quad in ASCT MMsm. Nice discussion of similarities (many) & differences (few) vs IMROZ.
CD38-VRd now the norm for many: time to shift algorithms to quad-eligible vs not regardless of ASCT plans!”
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study.
Authors: Saad Z. Usmani, et al.
